0001567619-22-021999.txt : 20221223 0001567619-22-021999.hdr.sgml : 20221223 20221223172726 ACCESSION NUMBER: 0001567619-22-021999 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20221221 FILED AS OF DATE: 20221223 DATE AS OF CHANGE: 20221223 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Disbrow Joshua R. CENTRAL INDEX KEY: 0001566240 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38247 FILM NUMBER: 221486195 MAIL ADDRESS: STREET 1: AMPIO PHARMACEUTICALS, INC. STREET 2: 5445 DTC PARKWAY, SUITE 925 CITY: GREENWOOD VILLAGE STATE: CO ZIP: 80111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AYTU BIOPHARMA, INC CENTRAL INDEX KEY: 0001385818 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 470883144 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 BUSINESS ADDRESS: STREET 1: 373 INVERNESS PARKWAY STREET 2: SUITE 206 CITY: ENGLEWOOD STATE: CO ZIP: 80112 BUSINESS PHONE: (720) 437-6580 MAIL ADDRESS: STREET 1: 373 INVERNESS PARKWAY STREET 2: SUITE 206 CITY: ENGLEWOOD STATE: CO ZIP: 80112 FORMER COMPANY: FORMER CONFORMED NAME: AYTU BIOSCIENCE, INC DATE OF NAME CHANGE: 20150609 FORMER COMPANY: FORMER CONFORMED NAME: AYTU BIOSCIENCE, INC. DATE OF NAME CHANGE: 20150609 FORMER COMPANY: FORMER CONFORMED NAME: Rosewind CORP DATE OF NAME CHANGE: 20070110 4 1 doc1.xml FORM 4 X0306 4 2022-12-21 0 0001385818 AYTU BIOPHARMA, INC AYTU 0001566240 Disbrow Joshua R. C/O AYTU BIOPHARMA, INC. 373 INVERNESS PARKWAY, SUITE 206 ENGLEWOOD CO 80112 1 1 0 0 Chief Executive Officer Common Stock 2022-12-20 4 D 0 80000 0 D 1151877 D On December 21, 2022, the reporting person and the Issuer determined to rescind 80,000 vested shares of restricted common stock originally granted to the reporting person on April 16, 2021. The vesting of the remaining restricted shares remains unchanged with 1/12 vesting on the first day of each quarterly anniversary of the grant, such that the restricted shares will be fully vested on the third anniversary of the grant, subject to the reporting person's continued service with the Issuer. /s/ Joshua R. Disbrow 2022-12-23